GLP 1 News and Research

RSS

Citrus compounds show zesty promise in type 2 diabetes management

Citrus compounds show promise in type 2 diabetes management, reducing blood glucose and mitigating metabolic complications without a clear threshold in humans for bioflavonoid efficacy.

2 Nov 2023

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.

22 Oct 2023

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Researchers investigate if oat polar lipid compounds improve glucose tolerance, gut hormonal responses, and triglyceridemia.

20 Oct 2023

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review. While effective in glycemic control and weight reduction, these drugs come with gastrointestinal side effects that may lead to treatment discontinuation.

17 Oct 2023

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

The interplay among chronic kidney disease, metabolic risk factors, and the cardiovascular system.

11 Oct 2023

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Researchers compared the effects of fermented and non-fermented Aronia melanocarpa berries on glycemic markers in Type 2 Diabetes Mellitus patients. Despite the berries' high antioxidant potential and past studies suggesting benefits, this rigorous trial found no significant impact on waist circumference, insulin sensitivity, or glucose levels.

10 Oct 2023

Health experts redefine cardiovascular disease risk, prevention and management

Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association's flagship journal Circulation.

9 Oct 2023

How is TikTok's #Ozempic trend impacting diabetes patients?

A recent study analyzed TikTok videos with the hashtag "Ozempic," highlighting the platform's influence on promoting the weight loss drug. The surge in popularity resulted in medication shortages for diabetes patients, emphasizing the need for careful monitoring and collaboration among health professionals and social media platforms.

5 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.

5 Oct 2023

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.

4 Oct 2023

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

At this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) experts will discuss if lasting remission from diabetes is feasible in the real-world setting.

4 Oct 2023

How do different polyphenol-rich foods impact chronic diseases?

The potential of phytochemicals in promoting a healthy human diet to combat chronic disease.

27 Sep 2023

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

The complex relationship between physical activity and energy balance – food intake versus energy expenditure – is still a challenge for science, especially in light of the rising worldwide prevalence of overweight and obesity

26 Sep 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

The study used a genome-wide association study (GWAS) to analyze random glucose levels in nearly half a million non-diabetic subjects, uncovering 150 distinct genetic signals, including 53 new ones, linked to glycemic traits and type 2 diabetes. The research also discovered a causal effect of random glucose and type 2 diabetes on lung function, identifying lung dysfunction as a new diabetes complication.

10 Sep 2023

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Groundbreaking research published today in Nature Genetics describes the largest-ever study into the genetics of random "round-the-clock" blood glucose levels.

8 Sep 2023

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children's health.

28 Aug 2023

GLP 1 News and Research

Citrus compounds show zesty promise in type 2 diabetes management

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Health experts redefine cardiovascular disease risk, prevention and management

How is TikTok's #Ozempic trend impacting diabetes patients?

GLP-1 weight loss drugs linked to heightened GI risks, says new study

GLP-1 agonists linked to higher risk for gastrointestinal complications

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

How do different polyphenol-rich foods impact chronic diseases?

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News